18F-氟比他班全身PET/MRI评估系统性淀粉样变沉积
这项前瞻性先导研究纳入9例疑似心脏淀粉样变患者,注射18F-氟比他班后行心脏动态及全身PET/MRI。5例左心室早期和延迟高摄取与淀粉样沉积相关,4例摄取低;延迟全身显像见骨髓、胃、脑等多器官异常摄取。作者认为该技术有望定位系统性淀粉样沉积并指导活检和疗效评估。
要点
- 9例疑似心脏淀粉样变患者中,5例左心室早期和延迟高摄取与淀粉样沉积相关,4例摄取低。
- 延迟全身PET/MRI见骨髓7例、胃弥漫5例和局灶1例、脑5例等异常18F-氟比他班摄取。
- 作者认为全身18F-氟比他班PET/MRI有望定位系统性淀粉样沉积并指导活检和疗效评估。
核心结论
- 作者认为全身18F-氟比他班PET/MRI有望用于定位系统性淀粉样沉积。
- 作者认为该技术可能提供受累器官的结构和功能信息,有潜力指导活检和评估治疗反应。
研究设计与样本
- 前瞻性先导研究,纳入9例61至86岁(均值±标准差69.4±8.6)由心脏淀粉样变门诊转诊的患者。
- 注射222至318.2 MBq(均值±标准差270.1±33.3)18F-氟比他班后即刻行心脏动态显像,注射后60至146.4分钟(均值±标准差98±33.4)行全身PET/MRI。
- 心脏MRI序列包括心电触发电影SSFP、T2加权和晚期钆增强成像;全身MRI序列包括MRAC和轴位T1加权成像。
主要发现
- 5例患者左心室早期高摄取和延迟高摄取与淀粉样沉积相关,4例患者心脏早期和延迟显像均为低摄取。
- 所有受试者均成功获得心脏功能测量。
- 延迟全身显像见异常18F-氟比他班蓄积:骨髓7例、胃弥漫5例和局灶1例、脑5例、唾液腺3例、舌3例、脾3例、骨骼肌3例、眼肌2例、甲状腺2例、胸膜2例、肾2例、肺2例。
关键数值与推荐
- 5例左心室早期和延迟高摄取与淀粉样沉积相关,4例心脏早期和延迟显像低摄取。
- 延迟全身显像异常摄取部位及例数:骨髓7例、胃弥漫5例和局灶1例、脑5例、唾液腺3例、舌3例、脾3例、骨骼肌3例、眼肌2例、甲状腺2例、胸膜2例、肾2例、肺2例。
临床怎么用
- 作者认为全身18F-氟比他班PET/MRI有望定位系统性淀粉样沉积,并可能提供受累器官的结构和功能信息。
- 作者认为该技术有潜力指导活检和评估治疗反应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Florbetaben, a 18F-labeled stilbene derivative (Neuraceq®, formerly known as BAY-949172), is a diagnostic radiopharmaceutical developed to visualize β-amyloid plaques in the brain. Here, we report a pilot study evaluating patients with suspected cardiac amyloidosis for systemic extent of disease. METHODS: We prospectively enrolled nine patients, 61-86 year old (mean ± SD 69.4 ± 8.6), referred from the cardiac amyloid clinic. First, dynamic imaging of the heart was acquired immediately after injection of 222-318.2 MBq (mean ± SD 270.1 ± 33.3) of 18F-florbetaben using the GE SIGNA PET/MRI. This was followed by a whole-body PET/MRI scan 60-146.4 min (mean ± SD 98 ± 33.4) after injection. Cardiac MRI sequences included ECG-triggered cine SSFP, T2-weighted, and late gadolinium-enhanced imaging. Whole-body MRI sequences included MRAC and axial T1-weighted imaging. RESULTS: High early uptake and delayed high uptake in the left ventricle correlated with amyloid deposition in five patients, while low uptake on early and delayed cardiac imaging was noted in four patients. Cardiac function measurements were successfully obtained in all participants. Areas of increased abnormal 18F-florbetaben accumulation were noted on delayed whole-body imaging in the bone marrow (seven patients), stomach (diffuse in five patients and focal in one patient), brain (five patients), salivary glands (three patients), tongue (three patients), spleen (three patients), skeletal muscles (three patients), ocular muscles (two patients), thyroid (two patients), pleura (two patients), kidneys (two patients), and lungs (two patients). CONCLUSIONS: Whole-body 18F-florbetaben PET/MRI is promising for localization of systemic amyloid deposition. This technique may provide important structural and functional information regarding the organs involved by disease, with potential to guide biopsy and evaluate response to treatment. TRIAL REGISTRATION: Clinicaltrials.gov registration: NCT03119558 .
引用
- Baratto L, Park SY, Hatami N, et al. 18F-florbetaben whole-body PET/MRI for evaluation of systemic amyloid deposition. EJNMMI Res. 2018. PMID: 30043115. doi:10.1186/s13550-018-0425-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。